Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction Antonio La Marca, Giovanni D’Ippolito

Slides:

Advertisements

Similar presentations

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

Advertisements

Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation Maaike L Haadsma, Henk Groen, Thea M Mooij, Curt W Burger, Frank JM.

Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis Sesh Kamal Sunkara, Jyotsna Pundir,

Kay Neumann, Georg Griesinger Reproductive BioMedicine Online

Vuong Thi Ngoc Lan, Nguyen Khanh Linh, Ho Manh Tuong, P. C

Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation Maaike L Haadsma, Henk Groen, Thea M Mooij, Curt W Burger, Frank JM.

Fresh and cryopreserved ovary transplantation and resting follicle recruitment Sherman Silber, Jorge Pineda, Kathleen Lenahan, Michael DeRosa, Jeffrey.

FMR1 gene CGG repeat variation within the normal range is not predictive of ovarian response in IVF cycles Scott J. Morin, Ashley W. Tiegs, Jason M.

Norbert Gleicher, Andrea Weghofer, David H. Barad

S.M. Nelson, A. La Marca Reproductive BioMedicine Online

Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response William L. Ledger, Bart C.J.M. Fauser, Paul.

Mid-luteal progesterone concentrations are associated with live birth rates during ovulation induction J.-C. Arce, A. Balen, P. Platteau, G. Pettersson,

Genetic variants associated with female reproductive ageing – potential markers for assessing ovarian function and ovarian stimulation outcome Triin.

Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF Bart C.J.M. Fauser, Michael.

N. la Cour Freiesleben, T. A. Gerds, J. L. Forman, J. D. Silver, A

Advanced glycation end product concentrations in follicular fluid of women undergoing IVF/ICSI with a GnRH agonist protocol Qi Yao, Yuanjiao Liang, Yong.

Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors Nikolaos P. Polyzos, Dominic Stoop, Christophe.

Patient-tailored ovarian stimulation for in vitro fertilization

A. La Marca, G. Sighinolfi, S. Giulini, M. Traglia, C. Argento, C

In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation

Ovarian response to 150 µg corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study Tamara Lerman, Marion Depenbusch,

Randomized trial comparing luteinizing hormone supplementation timing strategies in older women undergoing ovarian stimulation Hermann M. Behre, Colin.

Amir Wiser, Einat Shalom-Paz, Jordana H

HDlive ultrasound images in assisted reproduction treatment

New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation Giovanna Sighinolfi,

Anti-Müllerian hormone as a predictor of pregnancy following IVF

Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles Reshef Tal, David B. Seifer, Moisey Khanimov, Eliana.

Sherman Silber Reproductive BioMedicine Online

Why are reproductive cancers more common in nulliparous women?

Ovarian stimulation protocols for IVF: is more better than less?

K. Gersak, A. Veble Reproductive BioMedicine Online

Biomarkers of ovarian response: current and future applications

Hillary B. Alberta, Roberta M. Berry, Aaron D. Levine

Utility of age-specific serum anti-Müllerian hormone concentrations

Sarah McCredie, William Ledger, Christos A. Venetis

Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study A. Nasr Reproductive BioMedicine Online

Effect of energy expenditure and physical activity on the outcomes of assisted reproduction treatment Mert Kucuk, Fadime Doymaz, Bulent Urman Reproductive.

Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis Georg Griesinger, Robert Boostanfar, Keith.

Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa F. Olivennes, G. Trew,

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational.

John L. Yovich, Kevin N. Keane, Gayatri Borude, Satvinder S

Jyotsna Pundir, Sesh Kamal Sunkara, Tarek El-Toukhy, Yacoub Khalaf

Myotonic dystrophy type 1 and PGD: ovarian stimulation response and correlation analysis between ovarian reserve and genotype C. Dechanet, C. Castelli,

Dehydroepiandrostendione sulphate and prediction of live birth after IVF in young women with low anti-Müllerian hormone concentration Miro Šimun Alebić,

Impact of vitamin D levels on ovarian reserve and ovarian response to ovarian stimulation in oocyte donors Alberta Maria Fabris, Maria Cruz, Carlos Iglesias,

V Isachenko, E Isachenko, R Kreienberg, M Woriedh, JM Weiss

Michael J. Levy, William Ledger, Efstratios M. Kolibianakis, Pieta C

Does ovarian stimulation regimen affect IVF outcome

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Stephen C. Collins, Esther Chan Reproductive BioMedicine Online

Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,

Pietro Gambadauro, Ramesan Navaratnarajah

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

Genome-wide analysis shows no genomic predictors of ovarian response to stimulation by exogenous FSH for IVF Jeroen van Disseldorp, Lude Franke, Rene.

Jeff G. Wang, Nataki C. Douglas, Gary S. Nakhuda, Janet M

The Alpha Consensus Meeting on the professional status of the clinical embryologist: proceedings of an expert meeting Reproductive BioMedicine Online

Cumulative success rates following mild IVF in unselected infertile patients: a 3-year, single-centre cohort study Daniel Bodri, Satoshi Kawachiya, Michaël.

A. La Marca, S. M. Nelson, G. Sighinolfi, M. Manno, E. Baraldi, L

Is parental consanguinity associated with reduced ovarian reserve?

Propofol versus thiopental sodium as anaesthetic agents for oocyte retrieval: a randomized controlled trial Evangelia Goutziomitrou, Christos A. Venetis,

Predictive value of ovarian reserve markers in smoking and non-smoking women undergoing IVF Thomas Freour, Lionel Dessolle, Miguel Jean, Damien Masson,

Ovarian reserve screening before contraception?

Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH Basil C. Tarlatzis,

The significance of the number of CGG repeats and autoantibodies in premature ovarian failure Cem Fıçıcıoglu, Gazi Yildirim, Rukset Attar, Banu Kumbak,

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

John Yovich, James Stanger, Peter Hinchliffe

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Antonio La Marca, Martina Capuzzo Reproductive.

Presentation transcript:

Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction Antonio La Marca, Giovanni D’Ippolito Reproductive BioMedicine Online Volume 28, Issue 2, Pages 183-190 (February 2014) DOI: 10.1016/j.rbmo.2013.10.012 Copyright © 2013 Reproductive Healthcare Ltd. Terms and Conditions

Figure 1 Relationship between number of oocytes and potential predictors of ovarian response in women after treatment with recommended dose of corifollitropin alpha (from Ledger et al., 2010). (a) According to data from the ENGAGE and ENSURE trials, the mean number of oocytes retrieved was not dependent on drug exposure for women treated with the correct dose of 100 or 150 μg corifollitropin alpha based on their bodyweight. (b–d) As expected, the ovarian response depended mainly on predictors of ovarian response such as baseline FSH (b), AFC (c) and age (d). AUC=area under the receiver operating characteristic curve. Reproductive BioMedicine Online 2014 28, 183-190DOI: (10.1016/j.rbmo.2013.10.012) Copyright © 2013 Reproductive Healthcare Ltd. Terms and Conditions

Figure 2 OHSS in patients treated with corifollitropin alpha or recFSH. Data from the ENGAGE and ENSURE trials (pooled) (from Tarlatzis et al., 2012). Reproductive BioMedicine Online 2014 28, 183-190DOI: (10.1016/j.rbmo.2013.10.012) Copyright © 2013 Reproductive Healthcare Ltd. Terms and Conditions

Figure 3 The normogram of antral follicle count (AFC) in healthy eumenorrhoeic women. Using AFC >20 to exclude potential hyperresponder women from a treatment would result in the exclusion of a very low percentage of women (modified from La Marca et al., 2011). Reproductive BioMedicine Online 2014 28, 183-190DOI: (10.1016/j.rbmo.2013.10.012) Copyright © 2013 Reproductive Healthcare Ltd. Terms and Conditions

Figure 4 The relationship between functional ovarian reserve as measured by anti-Müllerian hormone (AMH) or antral follicle count (AFC) and the risk of ovarian hyperstimulation syndrome (OHSS). The linear relationship existing between AMH or AFC and ovarian response in IVF permits to predict increasing risk of OHSS for women with high AMH or AFC. Consequently maximal ovarian stimulation, however obtained, with either long or daily gondotrophins, should be avoided. Reproductive BioMedicine Online 2014 28, 183-190DOI: (10.1016/j.rbmo.2013.10.012) Copyright © 2013 Reproductive Healthcare Ltd. Terms and Conditions